Completed PHASE1 INTERVENTIONAL 4-arm NCT05665530

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies

Sponsor: BeiGene

Conditions Acute Myeloid Leukemia (AML) Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Chronic Myelomonocytic Leukemia (CMML) Diffuse Large B-cell Lymphoma (DLBCL) MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome Mantle Cell Lymphoma (MCL) Marginal Zone Lymphoma Myelodysplastic Syndrome (MDS) Myeloid Malignancies Richter's Syndrome T-cell Lymphoma

Interventions PRT2527 Venetoclax Zanubrutinib

Updated 20 times since 2023 Last updated: Jan 23, 2026 Started: Sep 12, 2023 Primary completion: Jun 12, 2025 Completion: Jan 21, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Acute Myeloid Leukemia (AML) and Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) and is currently completed. BeiGene leads this study, which shows 20 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Oct 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE1
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE1
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1

▶ Show 15 earlier versions

Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE1
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Mar 2023 — May 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2023 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeiGene
Prelude Therapeutics

Data source: Prelude Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bellinzona, Switzerland , Bethesda, United States , Bologna, Italy , Boston, United States , Busan, South Korea , Charlottesville, United States , Cologne, Germany , Créteil, France , Daegu, South Korea , Duarte, United States and 13 more locations